A two-step toward personalized therapies for prostate cancer
about
Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancerSerine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancersEmerging biomarkers of prostate cancer (Review)Cells of origin for cancer: an updated view from prostate cancer.Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer?SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
P2860
A two-step toward personalized therapies for prostate cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A two-step toward personalized therapies for prostate cancer
@ast
A two-step toward personalized therapies for prostate cancer
@en
A two-step toward personalized therapies for prostate cancer
@nl
type
label
A two-step toward personalized therapies for prostate cancer
@ast
A two-step toward personalized therapies for prostate cancer
@en
A two-step toward personalized therapies for prostate cancer
@nl
prefLabel
A two-step toward personalized therapies for prostate cancer
@ast
A two-step toward personalized therapies for prostate cancer
@en
A two-step toward personalized therapies for prostate cancer
@nl
P2860
P1476
A two-step toward personalized therapies for prostate cancer
@en
P2093
Owen N Witte
P2860
P356
10.1126/SCITRANSLMED.3002169
P407
P577
2011-03-01T00:00:00Z